Eurostars project E!8445 CellCleanUpSystems
| Reference number | |
| Coordinator | Liquid Biopsy AB |
| Funding from Vinnova | SEK 3 911 079 |
| Project duration | October 2013 - March 2017 |
| Status | Completed |
Important results from the project
The product meets the requirements of scientists and medics for a new and easily available sample type to follow cancer progression. Very high yields of a wide variety of tumor cells (70%) have been achieved. The cells can be subjected to further analyses, including by staining. The console has been laboratory validated. Cancer cells of widely different proprieties can be recovered, in line with the requirements of translational research and clinical diagnostics. Further outcomes, over and above the initial planning, were achieved as outlined below.
Expected long term effects
In addition to the planned outcomes the project has been awarded the CE mark by the Medical Products Agency (Läkemedelsverket) based on the ISO 13485 standard. The instrument is now in use for field studies to support translational cancer research projects. It is attracting paying customers. Feedback from customers indicate that the main areas for improvement now is in the ability to have a longer pre-analytical time period than 2 days, and to be able to perform detailed molecular downstream analyses of individual tumor cells. We expect a gradual increase in clinical usage.
Approach and implementation
The carefully elaborated plan worked well. There was for a while a slight delay that we could recover, without major concerns. The outcome was over and above our expectations, as stated above. The international cooperation worked well. The contacts could be effectively managed via email, mail and phone.